


June 13, 2012 02:13 ET
Pharming redeems final tranche of convertible bond
LEIDEN, THE NETHERLANDS--(Marketwire - Jun 13, 2012) - Biotech company Pharming Group NV ("Pharming" or "the Company") (EURONEXT: PHARM) today announced that it has redeemed the final tranche of its EUR8.4 million convertible bond. A total of 45,580,468 shares will be issued today to the bondholders under the terms and conditions of the bond, as announced in Pharming's press release on December 23, 2011, and following the approval of the increase in the Company's authorised share capital during the extraordinary general meeting of shareholders, which was held on February 3, 2012.
As of today, the number of outstanding shares has increased from 625,082,077 to 670,662,545.
About Pharming Group NV
Pharming Group NV is developing innovative products for the treatment of unmet medical needs. RUCONEST® (RHUCIN® in non-European territories) is a recombinant human C1 inhibitor approved for the treatment of angioedema attacks in patients with HAE in all 27 EU countries plus Norway, Iceland and Liechtenstein, and is distributed in the EU by Swedish Orphan Biovitrum (
This press release contains forward looking statements that involve known and unknown risks, uncertainties and other factors, which may cause the actual results, performance or achievements of the Company to be materially different from the results, performance or achievements expressed or implied by these forward looking statements.
Press release (PDF): [ http://hugin.info/132866/R/1619265/517164.pdf ]
This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Pharming Group N.V. via Thomson Reuters ONE [HUG#1619265]